CV Therapeutics, Inc.
http://www.cvt.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CV Therapeutics, Inc.
Indian Leaders Climb Into Generics And Biosimilars Top 10
In a year that has seen significant changes throughout the generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders. Meanwhile, companies lower down our ranking have enjoyed mixed fortunes, leading to a number of significant movements in this year’s Generics Bulletin Top 50.
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
Dr Reddy's Looking For 'Bigger Than Usual' Deals But Not In A Rush
Dr Reddy’s, rumored to be in the fray for Biogen’s biosimilars business, among other potential high-profile transactions, retains an appetite for ‘complementary’ deals, though management indicates it isn’t pursuing ‘transformative’ buys. The company continues to tap Chinese firms for innovative assets.
Dr Reddy's Looking For “Bigger Than Usual” Deals But Not In A Rush
Dr Reddy’s, rumored to be in the fray for Biogen’s biosimilars business, among other potential high-profile transactions, retains an appetite for ‘complementary’ deals, though management indicates it isn’t pursuing ‘transformative’ buys. The company continues to tap Chinese firms for innovative assets.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice